Your session is about to expire
← Back to Search
Pembrolizumab for Early-Stage Non-Small Cell Lung Cancer
Study Summary
This trial is testing whether the addition of the immunotherapy drug, Pembrolizumab, to standard of care following surgery for stage I NSCLC, will improve outcomes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not received a live vaccine within the last 30 days.I have an active tuberculosis infection.I have received chemotherapy, radiation, or immunotherapy for my lung cancer.My tumor has a specific change in the EGFR gene.I have or had lung inflammation not caused by infection, treated with steroids.I have a history of Hepatitis B or active Hepatitis C.I am 18 years old or older.I am not pregnant or breastfeeding, and if of childbearing age, I use effective birth control or practice abstinence.I have been mostly active and able to carry on all pre-disease activities without restriction in the last 28 days.My lung cancer is either smaller than 1 cm, larger than 4 cm, or is stage II, III, or IV.I have been treated with specific immune therapy targeting cancer.I am currently being treated for an infection.I have another cancer besides skin or in situ cancers that needed treatment in the last 3 years.I have not needed systemic treatment for an autoimmune disease in the last 2 years.You have a severe allergic reaction to pembrolizumab or any of its ingredients.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I have received an organ or tissue transplant from another person.I have a known history of HIV.
- Group 1: Arm B - Observation
- Group 2: Arm A- Pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are patients currently being recruited for this trial?
"That is correct. As of 8/9/2022, the clinical study was still recruiting patients which it will continue to do so at 11 different locations until a total of 368 people have participated."
How many individuals have signed up to participate in this research project?
"To run this experiment, the sponsor needs 368 participants that fit the inclusion criteria. Merck Sharp & Dohme LLC will carry out the trial at various locations, for example University of Nebraska Medical Center in Omaha and Indiana University Melvin and Bren Simon Cancer Center in Indianapolis."
In how many different areas is this trial being conducted?
"There are 11 locations in total where this trial is currently accepting patients. A few of these sites include University of Nebraska Medical Center, Indiana University Melvin and Bren Simon Cancer Center, as well as Penn State Cancer Institute."
Could you please share if Pembrolizumab has been studied before in other clinical trials?
"Pembrolizumab was first trialled a decade ago, at City of Hope. There are now 250 completed studies on this medication, with 1000 more currently underway across the globe. Many of these active trials are based in Omaha, Nebraska."
What are some of the more popular indications for Pembrolizumab?
"Pembrolizumab has shown to be an effective treatment for malignant neoplasms, unresectable melanoma, and microsatellite instability high."
What is the FDA's current stance on Pembrolizumab?
"Given that this is a Phase 2 trial - meaning there is some data supporting safety but not efficacy - our team at Power have given Pembrolizumab a score of 2 for safety."
Share this study with friends
Copy Link
Messenger